PuSH - Publication Server of Helmholtz Zentrum München

Verweij, J.* ; Casali, P.G.* ; Kotasek, D.* ; LeCesne, A.L.* ; Reichard, P.* ; Judson, I.R.* ; Issels, R.D. ; van Oosterom, A.T.* ; van Glabbeke, M.* ; Blay, J.-Y.*

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005.

Eur. J. Cancer 43, 974-978 (2007)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded.The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Imatinib; Cardiotoxicity; GIST
ISSN (print) / ISBN 0959-8049
e-ISSN 1879-0852
Journal European Journal of Cancer
Quellenangaben Volume: 43, Issue: 6, Pages: 974-978 Article Number: , Supplement: ,
Publisher Elsevier
Reviewing status Peer reviewed
Institute(s) CCG Tumor Therapy with Hyperthermia (IMI-KTH)